Eva M Satue-Gracia
Overview
Explore the profile of Eva M Satue-Gracia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clua-Espuny J, Hernandez-Pinilla A, Gentille-Lorente D, Muria-Subirats E, Forcadell-Arenas T, de Diego-Cabanes C, et al.
Biomedicines
. 2025 Jan;
13(1).
PMID: 39857703
In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3-5 individuals after the age of 55...
2.
Forcadell-Peris M, Vila-Corcoles A, de Diego-Cabanes C, Torras Vives V, Ochoa-Gondar O, Satue-Gracia E
J Infect Dis
. 2024 Dec;
PMID: 39676526
Background: Information concerning sex differences in pneumococcal vaccine effectiveness in adults is scarce. The main aim of this study is to compare the differences in clinical effectiveness of pneumococcal vaccination...
3.
Ochoa-Gondar O, Torras-Vives V, de Diego-Cabanes C, Satue-Gracia E, Vila-Rovira A, Forcadell-Perisa M, et al.
BMC Pulm Med
. 2023 Jun;
23(1):200.
PMID: 37291502
Background: Infection caused by Streptococcus pneumoniae, mainly invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP), are a major public health problem worldwide. This study investigated population-based incidence and risk of...
4.
Vila-Corcoles A, Ochoa-Gondar O, de Diego-Cabanes C, Satue-Gracia E, Torras-Vives V, Forcadell-Peris M, et al.
Vaccine X
. 2023 Feb;
13:100264.
PMID: 36798107
Background: At present, because of indirect effects derived from routine childhood immunisation, clinical benefits vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPsV23) and/or the 13-valent pneumococcal conjugate vaccine (PCV13)...
5.
Satue-Gracia E, Vila-Corcoles A, de Diego-Cabanes C, Vila-Rovira A, Torrente-Fraga C, Gomez-Bertomeu F, et al.
Med Clin (Engl Ed)
. 2022 May;
158(6):251-259.
PMID: 35492428
Objective: To analyse susceptibility/risk of suffering COVID-19 among adults with distinct underlying medical conditions. Methods: Population-based cohort study involving 79,083 individuals ≥50 years old in Tarragona (Southern Catalonia, Spain). Baseline...
6.
Gens-Barbera M, Hernandez-Vidal N, Vidal-Esteve E, Mengibar-Garcia Y, Hospital-Guardiola I, Oya-Girona E, et al.
Int J Environ Res Public Health
. 2021 Sep;
18(17).
PMID: 34501530
Objectives: (1) To describe the epidemiology of patient safety (PS) incidents registered in an electronic notification system in primary care (PC) health centres; (2) to define a risk map; and...
7.
Satue-Gracia E, Vila-Corcoles A, de Diego-Cabanes C, Vila-Rovira A, Torrente-Fraga C, Gomez-Bertomeu F, et al.
Med Clin (Barc)
. 2021 Jun;
158(6):251-259.
PMID: 34074472
Objective: To analyse susceptibility/risk of suffering COVID-19 among adults with distinct underlying medical conditions. Methods: Population-based cohort study involving 79,083 individuals ≥50 years old in Tarragona (Southern Catalonia, Spain). Baseline...
8.
Vila-Corcoles A, Ochoa-Gondar O, Satue-Gracia E, Torrente-Fraga C, Gomez-Bertomeu F, Vila-Rovira A, et al.
BMJ Open
. 2020 Dec;
10(12):e041577.
PMID: 33303459
Objective: To investigate possible relationships between pre-existing medical conditions (including common comorbidities and chronic medications) and risk for suffering COVID-19 disease in middle-aged and older adults. Design: Population-based retrospective cohort...